ÔĽŅ Faculty Profile, National Health Research Institutes, Taiwan

Faculty Profiles

Ih-Jen Su, M.D., Ph.D.

Distinguished Investigator and Director
Division of Infectious Diseases


Ph.D., Pathology, Institute of Pathology, National Taiwan University, 1988.
M.D., Medicine, National Taiwan University Medical College, 1976.


  • Distinguished Investigator and Director, Division of Clinical Research, National Health Research Institutes, Taiwan
  • Professor, Institute of Clinical Medicine, National Cheng-Kung University, Taiwan
  • Director General, Center for Disease Control. (CDC), Taiwan
  • Professor and Chairman, Department of Pathology, National Cheng Kung University Hospital Medical School, Taiwan
  • Director, Institutes of Molecular Medicine and Clinical Medicine, National Cheng-Kung University Medical School, Taiwan
  • Professor and Chairman, Department and Institute of Pathology, National Taiwan University Medical College and Hospital, Taiwan
  • President, Taiwan Society of Pathology, Taiwan
  • Fellow Member, International Lymphoma Study Group
  • Scientific Consultant, CDC (Center for Disease Control), Department of Health, Taiwan


    Dr. Suís major research interest is on the pathogenesis and targeted therapy of virus-associated malignancies, including EBV-associated T cell lymphoma and hemophagocytic syndrome and HBV-related hepatocellutar carcinoma. In the past 20 years, he identified that EBV can infect T cells and cause T cell lymphoma and hemophago-cytic syndrome. His team clarified the signal pathway and target for therapy. Recently, they identified the HBV pre-S mutants as the potential oncoproteins through the ER stress signals. By identifying the specific signal pathway, they are now applying PPAR agonists and NFkB inhibitors for the prevention and therapy of these virus-associated immune disorders and human cancers.


    Dr. Suís laboratory is the leading group in the study of EVB-associated T cell lymphoma and hemophagocytic syndrome in the world. They first identified KSHV / HHV-8 in non-AIDS Kaposiís sarcoma. Their group also first identified HBV pre-S mutants in ground glass hepatocytes and clarified the biologic significance and its potential role in hepatocarcinogenesis. He has published a total of more than 200 papers in the journals like Lancet, Blood, Journal of Clinical Investigation, and Am. J. Pathol. During the SARS period, he served as the Director General of Taiwan CDC. He also coordinates the task force for infectious diseases like influenza, enteroviruses, HIV, and tuberculosis.


  • Ho Chi Ming Award, Vietnam, 2006
  • Associate Editor, Cancer Science, 2005-present
  • Distinguished Research Award (1991,1995, 1997); Special Appointed Award ( 2002, 2005), National Science Council, Taiwan
  • First Class Health Award (SARS Control), Department of Health, 2005
  • Lai Ho Award in medical service, 2000
  • Outstanding Award in Cancer Research, Dr. Hsu Chien-tienís Foundation
  • Fellow member, International Lymphoma Study Group, 1997-present
  • Ten Outstanding Young Person (TOYP) Award, 1990


    1.Chuang HC, Lay JD, Hsieh WC, Chang Y and Su IJ. EBV LMP-1 downregulates TNFR1 and confers resistance to TNF-a-induced apoptosis in T cells. Am J Pathol, 170;1607-1617, 2007.
    2.Chuang HC, Lay JD, Hsieh WC, Wang HC, Chang Y, Chuang SE, Su IJ. Epstein-Barr virus LMP1 inhibits the expression of SAP gene and upregulates Th1 cytokines in the pathogenesis of hemophagocytic syndrome. Blood, 106(9):3090-6, 2005.
    3.Wang HC, Chang WT, Chang WW, Lei HY, Lay MD and Su IJ. Hepatits B Virus pre-S2 mutant upregulates cyclin A and induces nodular proliferation of hepatocytes. Hepatology, 41:761-770, 2005.
    4.Ho MS, Su IJ: Preparing to prevent severe acute respiratory syndrome and other respiratory infections. Lancet (Infections Disease), 4 : 684-689, 2004.
    5.Wang HC, Wu HC, Chen CF, Lei HY, Su IJ. Different types of ground glass hepatocytes in chronic HBV infection centain specific pre-S mutants that may induce ER stress. Am J Pathol, 163: 2441-2449, 2003.